CXCL9 and non-small cell lung carcinoma: The results obtained in this clinical study suggested that impaired CXCL9 production and dysbiosis in BALF might also be present in the lung TME of patients with NSCLC, which could reduce the sensitivity to PD-1–blocking treatment.